Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases
Open accessThe DOI matches its Crossref record; 209 of the 211 references it cites were found in a registry or an index.
Abstract
The glucagon-like peptide-1 (GLP-1) is a pleiotropic hormone well known for its incretin effect in the glucose-dependent stimulation of insulin secretion. However, GLP-1 is also produced in the brain and displays a critical role in neuroprotection and inflammation by activating the GLP-1 receptor signaling pathways. Several studies in vivo and in vitro using preclinical models of neurodegenerative diseases show that GLP-1R activation has anti-inflammatory properties. This review explores the molecular mechanistic action of GLP-1 RAS in relation to inflammation in the brain. These findings update our knowledge of the potential benefits of GLP-1RAS actions in reducing the inflammatory response. These molecules emerge as a potential therapeutic tool in treating neurodegenerative diseases and neuroinflammatory pathologies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Schematic processing of proglucagon. NTS: nucleus of the solitary tract; GRPP: glicentin-related polypeptide; IP-1: intervening peptide-1; IP-2: intervening peptide-2; GLP-1: glucagon-like peptide-1; GLP-2: glucagon-like peptide-2; MPGF: major proglucagon fragment; PCSK1: prohormone convertase 1/3; PCSK2: prohormone convertase 2. Modified from [36]. Created with Biorender.com.](https://figures.cochat.ai/paper-figures/b03e4d8dfc0940aca0935cc5c49966ed/anti-inflammatory-effects-of-glp-1-receptor-activation-in-the-brain-in-figure-1.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1RAs can alleviate neuroinflammation by acting on the nervous system, thereby offering additional relief from pain in patients.6,409,410”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“GLP-1RAs play a neuroprotective role in neurons by facilitating neuronal survival and promoting neuronal growth, thereby preserving the structural and functional integrity of synapses.6,14”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“GLP-1RAs are anti-inflammatory because they control the signals that immune cells send and receive.”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [24]
The cited source says what the claim attributes to it.
In the citing paper
“Although it is well established that GLP-1RA’s anti-inflammatory effects originate from their impact on immune cell signaling, additional in-depth investigation into the underlying molecular pathways is required.”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [24]
The cited source says what the claim attributes to it.
In the citing paper
“GLP-1RAs may modulate inflammatory responses since GLP-1 receptors are present in immune cells such as macrophages, monocytes, and lymphocytes.”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [24]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Polazzi, E., Mengoni, I., Caprini, M., Peña-Altamira, E., Kurtys, E., & Monti, B. (2013) · Neurosignals · doi:10.1159/000337115 · Cited by 8,994
Neurotoxic reactive astrocytes are induced by activated microglia
Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., Bennett, M. L., Münch, A. E., Chung, W.-S., Peterson, T. C., et al. (2017) · Nature · doi:10.1038/nature21029 · Cited by 7,971
Origin and physiological roles of inflammation
Medzhitov, R. (2008) · Nature · doi:10.1038/nature07201 · Cited by 6,618
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Neural regulation of endocrine and autonomic stress responses
Ulrich-Lai, Y. M., & Herman, J. P. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2647 · Cited by 3,318 · cited 2×
“Other areas of the brainstem that control the autonomic function including the limbic forebrain regions [36,48,50], areas of the mesolimbic reward system related to control of feeding and motivation to feed [36,51,52], or structures implicated in the regulation of the stress response and the HPA axis, learning and mem…”
BackgroundKnopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00269-y · Cited by 2,606
Kiernan, M. C., Vucic, S., Cheah, B. C., Turner, M. R., Eisen, A., Hardiman, O., Burrell, J. R., & Zoing, M. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61156-7 · Cited by 2,603
Reich, D. S., Lucchinetti, C. F., & Calabresi, P. A. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1401483 · Cited by 2,491
Cited by
Items 101–152 of 152
Mechanism for the association between diabetes or anti‐diabetic medications and incident dementia
Araki, A. (2025) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.70066 · Cited by 1
“6,7 Liraglutide may improve cognitive function by inhibiting serine phosphorylation of IRS-1 via activation of JNK by soluble A β and by reversing insulin signaling impairment 3 and may inhibit brain injury in diabetic animals via reduction of HMGB1 and MMP-9.”
Conforti, A., Cifuentes‐González, C., Agrawal, R. V., & Agrawal, R. V. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104786 · Cited by 1
Li, X., Liu, Y., Wang, F., Zhang, F., Zhang, L., Dang, Y., & Qi, X. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-026-07958-4 · Cited by 1
Long, H., Xing, C., Yang, X., Wang, S., Tian, B., Cheng, J., Yao, Y., & Sui, B. (2025) · Medicine · doi:10.1097/md.0000000000045814 · Cited by 1
Li, K., Kong, Y., & Chen, T. (2025) · Microbial Cell Factories · doi:10.1186/s12934-025-02901-y · Cited by 1
“In addition, GLP-1 itself also involves in neuroprotection and is closely linked to the pathogenesis of PD [85].”
Secondary Metabolites: Therapeutic Tools for Tackling Neurodegenerative Diseases
Housseini, A. E., Rachmoune, K., Aitbaba, A., Hamdan, Y. A., Armadi, I., Harkat, C., Laghzaoui, E.-M., Kahime, K., Hidan, M. A. E., Laaradia, M. A., et al. (2026) · IGI Global eBooks · doi:10.4018/979-8-3373-1365-8.ch005 · Cited by 3
GLP ‐ 1RAs versus metformin and Parkinson's risk in type 2 diabetes
Sun, M., Wang, X., Lu, Z., Yang, Y., Lv, S., Miao, M., Chen, W., Wu, S., & Zhang, J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70459 · Cited by 1
Gadelmawla, A. F., Elettreby, A. M., Aldawsari, R. A., Asiri, A., Almutairi, B., Murayyi, R. A., Alsuhaibani, A., Suhaqi, L., Aloufi, S., Althobaiti, S., et al. (2026) · Neurological Sciences · doi:10.1007/s10072-026-08843-6 · Cited by 1
Verma, J., Singh, R. K., Paul, S., Gupta, S., Gupta, A. K., Sharma, A. K., Kumar, M., Mehan, S., Samant, R., & Tongra, M. (2026) · Metabolic Brain Disease · doi:10.1007/s11011-026-01866-0 · Cited by 1
GLP-1 Receptor Agonists in Neurological Disorders: From Mechanisms to Clinical Translation
Li, P., Gao, Y., & (20030), W. L. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s613616 · Cited by 2
“37 What is more, when microglia get too activated, they can turn astrocytes into a toxic form that damages nearby neurons.”
Targeting the GLP-1 receptor pathways for dual management of obesity and depression
Keswani, R., & Bhatt, S. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104727 · Cited by 2
Büyükcavlak, M., Mehmet, S. A. R. I., Çiftci, C., Ayçiçek, S. T., Oltulu, P., & Çiftçi, S. (2026) · Journal of Anesthesia · doi:10.1007/s00540-026-03813-w · Cited by 1
Vignera, S. L., & Condorelli, R. A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146116 · Cited by 1
Thome, A. D., Wang, J., Faridar, A., Zhao, W., Saetzler, V., Beers, D. R., & Appel, S. H. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177855 · Cited by 2
“…or production of IL-6, IL-1 β , and TNF and promoting transcriptional and metabolic programs associated with less inflammatory myeloid states [21–23 , 34– LD-IL2 acts primarily through preferential engagement of the high-affinity IL-2 receptor expressed by Tregs, with downstream…”
Advances in Disease Modifying Therapies for Parkinson's Disease
Hassanzadeh, K., & Mouradian, M. M. (2025) · Wiley eBooks · doi:10.1002/9783527844678.ch2 · Cited by 1
Vashisht, R., Dhruva, S. S., Patel, A. R., Dahm, L., Morris, P., Gonzalez, D. M., Follett, R., Sirota, M., Singh, K., Han, C., et al. (2025) · SSRN Electronic Journal · doi:10.1101/2025.08.13.25333579 · Cited by 2
Georgakopoulos, A. (2025) · doi:10.14293/pr2199.001770.v1
Prajapati, P., Shafi, N., Pachchipulusu, V., Fatima, N., Noorien, S., Biswas, S. K., Narula, A., Aishwarya, K., Prajapati, S. D., Patel, M. K., et al. (2025) · medRxiv · doi:10.1101/2025.09.01.25334855
GLP-1 in multiple sclerosis: preclinical evidence, clinical prospects and future directions
Satanovsky, D. (2025) · INTERNATIONAL NEUROLOGICAL JOURNAL · doi:10.22141/2224-0713.21.7.2025.1218
Kotecha, P., Lee, Y. A., Presti, M. F., Guo, Y. M., Bian, J., & Guo, J. S. (2025) · medRxiv · doi:10.64898/2025.11.24.25340763
Hawkins, A., & McCoy, R. G. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doc25-0020
Li, S. Y., Sonti, A., Kaelber, D. C., Ben-Israel, D., Bowles, A., Reddy, D., & Kelly, M. L. (2026) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2026.111905 · Cited by 2
Yang, W., Yang, Z., Lu, S., Meng, L., Yang, F., Liu, H., & Wang, J. (2026) · Experimental Brain Research · doi:10.1007/s00221-026-07274-1
Feng, P., Liu, Z., Zhai, X., Bai, B., Gao, H., Hao, W., Li, T., & Hölscher, C. (2026) · Peptides · doi:10.1016/j.peptides.2026.171485
Zhang, Z.-R., She, L., Cao, Y., & Chen, Y.-W. (2026) · World Journal of Hepatology · doi:10.4254/wjh.v18.i4.116074
Breit, S. (2026) · Journal of Psychiatry and Brain Science · doi:10.20900/jpbs.20260006
“Emerging evidence from in vitro and in vivo studies suggests that GLP-1RAs have anti-inflammatory properties [219–221].”
New Adjuvant Therapies for Obesity-Related Disorders Associated with Meta-Neuroinflammation
Coluzzi, F., Cornali, K., Scerpa, M. S., & Noce, A. (2026) · Pharmaceuticals · doi:10.3390/ph19050786
“The pleiotropic effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs), already approved by the Food and Drug Administration for the treatment of type 2 DM and obesity [174], could be repurposed for the treatment of neuroinflammation and neurodegenerative pathways [175–177].”
Glucagon-Like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease: A Narrative Review
Desai, A., Habib, H., Wahbeh, L., & Farraye, F. A. (2026) · Gastro Hep Advances · doi:10.1016/j.gastha.2026.101023
GLP-1 receptor agonists in neuroinflammation: a novel therapeutic target?
Silva, P. B. P., de Castro, R. M., dos Santos, J. P., Gouveia, H. J. C. B., & Toscano, A. E. (2026) · Nutritional Neuroscience · doi:10.1080/1028415x.2026.2680999
Туркина, С. В. (2026) · Consilium Medicum · doi:10.26442/20751753.2026.5.203661
GLP-1 agonist and neuroprotection in Stroke and Parkinson’s disease: A systematic review
Parekh, D. S., Kudaiarov, D., Inban, P., Agrawal, A., Prajjwal, P., & Tariq, H. (2026) · Disease-a-Month · doi:10.1016/j.disamonth.2026.102151
GLP-1 receptor agonists in addiction and affective disorders: Implications for dual disorders
Seijas‐Amigo, J., Salgado‐Barreira, Á., Eiras, S., Arias-Rivas, S., Rodríguez-Carnero, G., & González‐Juanatey, J. R. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111802 · Cited by 3
Novel treatments for Parkinson’s disease
Yin, Y., Gao, J., Zhang, K., Meng, F. D., & Feng, T. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004163
Bi, Q., Zhang, L., Zhang, J. H., (91924), X. W., Zuo, C., Zhao, S., Wang, Z. L., Zhao, Z., & Wan, H. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05635-9 · Cited by 1
“Experimental studies have shown that GLP-1 receptor agonists may regulate neuroinflammation, reduce oxidative stress, improve mitochondrial function, protect synapses, and promote neuronal survival (Hölscher 2014; Diz-Chaves et al. 2022; Kopp et al. 2022).”
Ravi, T., Dash, K., Barman, D. K., Kwon, H., Mishra, M., & Sahoo, H. (2026) · Biopolymers · doi:10.1002/bip.70113
Xu, W., Lu, C., Xu, J., & Wang, L. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106846
Gastrointestinal and Extra-Metabolic Effects of GLP-1-Based Therapies: A Narrative Review
Geetha, S. S., Abbas, S. M. N. E., Saadi, A. R., Nair, S. A., & Elhassan, O. A. A. (2026) · JUNIOR RESEARCHERS · doi:10.52340/jr.2026.04.02.06
Yu, T., Mai, Q., Wang, Q., Pan, M., Xiong, Y., Kuang, L., & Liu, H. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1894856
Wohlfeld, C., Blas, A., Woodruff, J., Frick, M., Maciejewska, N., Patel, A., Grillo, C. A., Reagan, L. P., & Fadel, J. R. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.03.742612
“Preclinical studies demonstrate that GLP-1 agonists and/or central GLP-1 signaling attenuate neuroinflammation, mitigate tau pathology, improve neurotrophic support, facilitate adult neurogenesis in the hippocampus, and other mechanisms [21-28].”
Lin, C.-H., Hung, P., Chung, M., Wu, L.-Y., & Chung, C. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100645 · Cited by 2
“GLP-1 RAs have shown promise in protecting against cognitive decline by improving synaptic plasticity, cell survival, and brain markers such as cerebral glucose metabolism and cerebral perfusion [16].”
Cui, H., Nisar, A., Duan, Z., Mao, J., Zhu, H., Li, L., Cao, X., He, Y., & Li, W. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108443
Rethinking T2DM Care: GLP-1 Therapy and Strength Training Combined
Patel, J. H., & Alfadhli, L. (2026) · Health Science Inquiry · doi:10.29173/6n2qsv59
Brucar, L. R., Miller, K. M., & Volkow, N. D. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106990
Aberrant microglial responses shape hypothalamic circuits in anorexia nervosaPreprint
Xu, J., Erskine, E., Eramo, B., Zimmer, K., Camoglio, C., Chaudhary, M., Feng, T., Orhan, F., Welch, E., Selander, L., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.18.748216
Klusek, K., Batory, M., Jakubowski, J., Kraska, K., Krasucka, N., Zynkowska, A., Skrzyniarz, A. M., Kiełbus, M., Oziębło, J., & Kijowska, M. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6114
Diabetes‐Associated Cognitive Impairment: Pathophysiology and Emerging Therapies
Corbali, O., Menon, P., Corbali, H. I., Jagannathan, R., & Levey, A. I. (2026) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.70487
“Glucagon-like peptide-1 (GLP-1) is a pleiotropic incretin hormone that enhances insulin secretion, delays gastric emptying, and reduces appetite and food intake [193, 194].”
Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review
Chang, A. Y., & Mateen, F. J. (2026) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.70547
“In preclinical studies, expression of GLP-1R in the CNS is not well elucidated and may vary between species and technique of analysis [75].”
Shoukry, H. S., Harbieh, I., Harbieh, M., Elbana, A. K., Fahmy, E. K., A, A. M. M., Esmaeel, S. E., Alruwaili, M. G., Rehman, A. G. A., Elshafey, S., et al. (2026) · Journal of Pioneering Medical Science · doi:10.47310/jpms2026150903
“Furthermore, Ex-4 has been shown to Figure 1: Graphical Abstract inhibit the assembly of the NLRP3 inflammasome, subsequently reducing the maturation and release of pro-inflammatory cytokines such as IL-1 β and IL-18 [3].”
InfluentialOtto, B., Zantvoord, J. B., Siskind, D. J., & Vermeulen, J. M. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111978
Lakshmi, S. M., Singh, V., Vanangamudi, M., Taj, T., Shahin, H., Nath, R., Dutta, G., Avvari, S. K., Sridhar, S. B., Panigrahy, U. P., et al. (2026) · European Journal of Neuroscience · doi:10.1111/ejn.70718
Mehta, S., Thangudu, S., Haghverdi, G., Sekar, P. D. M., & Paulmurugan, R. (2026) · ACS Nano Medicine · doi:10.1021/acsnanomed.6c00189
Reczka, K., Zalewska, Z., Szymkowiak, J., & Woźniak, M. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(52).2026.6289
“[8 , 12, 14, 21, 27, 29]”
Metadata
- Authors
- Diz-Chaves, Y., Mastoor, Z., Spuch, C., González-Matías, L. C., & Mallo, F.
- Affiliations
- Universidade de Vigo (ES)
- Translational Neuroscience Research Group, Galicia Sur Health Research Institute, CIBERSAM, Hospital Álvaro Cunqueiro, Bloque Técnico, Planta 2, Sala de Investigación, Estrada Clara Campoamor, 341, 36212 Vigo, Spain
- Corresponding author
- Diz-Chaves, Yolanda
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-08-24
- Volume
- 23
- Issue
- 17
- Pages
- 9583
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC9455625
- OpenAlex
- W4293001879
- Cited by
- 148
- References
- 211
- Citations by year
- 2026: 52 · 2025: 66 · 2024: 21 · 2023: 9
- FWCI
- 2.47
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Investigo Institutional repository of UVigo (Universidade de Vigo) (submittedVersion, cc-by)
- Funders
- European Union Grant Alehoop (H2020-BBIJTI-2019-887259, ED431G/02)
- Xunta de Galicia (Centro singular de Investigación de Galicia accreditation 2016–2019) (H2020-BBIJTI-2019-887259, ED431G/02)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- glucagon-like peptide-1, GLP-1 receptor, neuroinflammation, neurodegenerative diseases, neuroprotection, anti-inflammatory activity, brain, GLP-1 receptor signaling, therapeutic target
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Brain, Humans, Inflammation, Neurodegenerative Diseases, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.